Roche Holding AG (RHHBY)
| Market Cap | 324.41B +21.7% |
| Revenue (ttm) | 79.90B +1.5% |
| Net Income | 16.24B +55.6% |
| EPS | 20.23 +55.6% |
| Shares Out | n/a |
| PE Ratio | 19.97 |
| Forward PE | 15.91 |
| Dividend | 0.97 (1.88%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | 277,078 |
| Open | 51.89 |
| Previous Close | 52.55 |
| Day's Range | 51.03 - 51.90 |
| 52-Week Range | 37.51 - 60.85 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 56.66 (+10.45%) |
| Earnings Date | Jul 23, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for RHHBY stock is "Buy." The 12-month stock price target is $56.66, which is an increase of 10.45% from the latest price.
News
Roche's Divarasib Meets Primary Endpoint In Phase 3 Krascendo 1 Study For Treating Lung Cancer
(RTTNews) - Roche Holdings AG (RHHBY), a pharmaceutical company, on Thursday announced that the Phase 3 Krascendo 1 trial for the KRAS12C-inhibitor Divasarib vs. sotorasib and adagrasib had met its pr...
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Experimental drug, divarasib, showed meaningful improvements in both patients' overall survival and the time they survived without the disease worsening.
Genentech's Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today positive results from the Phase III Krascendo 1 study evaluating diva...
[Ad hoc announcement pursuant to Art. 53 LR] Roche's divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
Basel, 02 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today positive results from the phase III Krascendo 1 study evaluating divarasib, an investigational next-generation KRAS G12C inhibi...
Roche to set up digital technology hub in Hyderabad
Swiss Drugmaker’s Second Hub In India To Become Operational in Q1 Of 2027
Old cancer drug may help restore fertility for certain women
We also cover a large study that should allay fears of people who should be taking cholesterol-lowering statins.
Genentech announces priority review for Enspryng
Genentech, a member of the Roche (RHHBY), announced that the FDA has accepted and granted priority review to a supplemental biologics license application, or sBLA, for Enspryng for the treatment…
Roche Secures FDA Priority Review Of Enspryng In Thyroid Eye Disease; Decision Due October 2026
(RTTNews) - Genentech, a member of Roche Holding AG (RHHBY), announced on Tuesday that it has secured the US Food and Drug Administration (FDA) priority review of its supplemental Biologics License Ap...
FDA Grants Priority Review To Genentech's Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted and gra...
Roche announces launch of AXELIOS 1, a next-gen sequencing platform
Roche (RHHBY) announced the launch of AXELIOS 1 based on SBX technology, with a combination of accuracy, speed, flexibility, scalability and cost efficiency that addresses critical bottlenecks in geno...
Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip
Swiss pharma and diagnostics giant Roche on Monday launched its long-awaited Axelios gene sequencer, in a bid to challenge U.S. firm Illumina's leadership in next-generation sequencing.
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
Basel, 29 June 2026 — Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the launch of AXELIOS 1 based on the innovative SBX technology, with a unique combination of accuracy, speed, flexibility, scal...
Swiss pharma at risk of US trade investigation, industry body says
The United States could open a trade investigation into Switzerland's pharmaceutical industry similar to the one initiated last week against Germany, the head of Swiss industry body Interpharma said...
Louth GAA FL Round-up - Div 2: O’Raghallaighs pick up vital points as Roche open six-point lead at the top
Exelixis Announces STELLAR-303 Trial Results For Zanzalintinib Combination
(RTTNews) - Exelixis, Inc. (EXEL) on Monday reported final analysis results from the phase 3 STELLAR-303 trial evaluating zanzalintinib in combination with Roche's Tecentriq versus regorafenib in prev...
The U.S. has launched a trade investigation into a German plan to cut spending on pharmaceuticals, a move that could result in fresh tariffs
The investigation comes after Berlin said it would require drugmakers to offer bigger discounts on medicines.
U.S. opens tariff probe targeting Germany's drug pricing policies
The U.S. said the probe will examine whether "persistent underpayment" for medicines by Germany is discriminatory. "President Trump has made clear that American patients should not be shouldering a di...
Roche (RHHBF) Receives FDA Acceptance for Lunsumio VELO Label Expansion
Roche (RHHBF) Receives FDA Acceptance for Lunsumio VELO Label Expansion
Genentech says FDA accepts sBLA for for Lunsumio VELO
Genentech, a member of the Roche (RHHBY) Group, announced that the U.S. FDA has accepted the company’s supplemental Biologics License Application for Lunsumio VELO, as a subcutaneous formulation, in c...
FDA Accepts Genentech's SBLA For Lunsumio-Polivy In LBCL; Decision Slated For February 2027
(RTTNews) - Genentech, a unit of Roche Holding AG (RHHBY), announced that the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application (sBLA) for Lunsumio VELO as ...
FDA accepts supplemental Biologics License Application for Roche's Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
Basel, June 18, 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) fo...
FDA Accepts Supplemental Biologics License Application for Genentech's Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com...
FDA approves first generic version of Roche's flu drug
The U.S. Food and Drug Administration approved the first generic version of Roche's Xofluza, a single-dose flu medicine for certain patients aged five years and older, the regulator said on Wednesda...
Drugmakers race to find a place in the next wave of obesity drugs
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent Am...
Roche Secures FDA Approval For First PTEN IHC Companion Diagnostic In Prostate Cancer
(RTTNews) - Roche (RHHBY) announced that the VENTANA PTEN (SP218) RxDx Assay has become the first immunohistochemistry (IHC) companion diagnostic test to receive approval from the U.S. Food and Drug A...